Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature

Am J Hematol. 2015 Sep;90(9):E183-4. doi: 10.1002/ajh.24066. Epub 2015 Jul 22.

Authors

Taxiarchis V Kourelis¹, Jan C Buckner², Naseema Gangat¹, Mrinal M Patnaik¹

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota.
² Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.

PMID: 26010271
DOI: 10.1002/ajh.24066

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Anemia, Aplastic / chemically induced*
Anemia, Aplastic / mortality
Anemia, Aplastic / pathology
Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Agents, Alkylating / adverse effects*
Astrocytoma / drug therapy*
Astrocytoma / mortality
Astrocytoma / pathology
Bone Marrow / drug effects*
Bone Marrow / pathology
Brain Neoplasms / drug therapy*
Brain Neoplasms / mortality
Brain Neoplasms / pathology
Dacarbazine / administration & dosage
Dacarbazine / adverse effects
Dacarbazine / analogs & derivatives*
Female
Humans
Male
Middle Aged
Survival Analysis
Temozolomide
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Dacarbazine
Temozolomide